{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T12:58:12Z","timestamp":1762865892457,"version":"3.41.2"},"reference-count":20,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1097\/igc.0b013e318234f927","type":"journal-article","created":{"date-parts":[[2011,12,6]],"date-time":"2011-12-06T04:09:46Z","timestamp":1323144586000},"page":"70-75","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Intravenous\/Intraperitoneal Paclitaxel and Intraperitoneal Carboplatin in Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Carcinoma"],"prefix":"10.1016","volume":"22","author":[{"given":"Shoji","family":"Nagao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norihiro","family":"Iwasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Kurosaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadaaki","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rie","family":"Ohishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosei","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Goto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichi","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1097\/IGC.0b013e318234f927_bb0005","doi-asserted-by":"crossref","first-page":"845","DOI":"10.7326\/0003-4819-97-6-845","article-title":"Phase I\/pharmacokinetic study of intraperitoneal cisplatin with systemic thiosulfate protection","volume":"97","author":"Howel","year":"1982","journal-title":"Ann Intern Med."},{"key":"10.1097\/IGC.0b013e318234f927_bb0010","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1056\/NEJM199612263352603","article-title":"Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer","volume":"335","author":"Alberts","year":"1996","journal-title":"N Engl J Med."},{"key":"10.1097\/IGC.0b013e318234f927_bb0015","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","volume":"19","author":"Markman","year":"2001","journal-title":"J Clin Oncol."},{"key":"10.1097\/IGC.0b013e318234f927_bb0020","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Phase III randomized trial of intravenous cisplatin and paclitaxel versus an intensive regimen of intravenous paclitaxel, intraperitoneal cisplatin, and intraperitoneal paclitaxel in stage III ovarian cancer: a Gynecologic Oncology Group study","volume":"354","author":"Armstrong","year":"2006","journal-title":"N Engl J Med."},{"key":"10.1097\/IGC.0b013e318234f927_bb0025","doi-asserted-by":"crossref","first-page":"4528","DOI":"10.1200\/JCO.2006.06.0376","article-title":"Intraperitoneal chemotherapy in ovarian cancer remains experimental","volume":"24","author":"Gore","year":"2006","journal-title":"J Clin Oncol."},{"key":"10.1097\/IGC.0b013e318234f927_bb0030","unstructured":"National Cancer Institute. NCI Issues clinical announcement for preferred method of treatment for advanced ovarian cancer. Available at: http:\/\/www.cancer.gov\/newscenter\/pressreleases\/ IPchemotherapyrelease. Accessed November 6, 2006."},{"key":"10.1097\/IGC.0b013e318234f927_bb0035","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ygyno.2009.04.001","article-title":"Practice patterns of intraperitoneal chemotherapy in women with ovarian cancer","volume":"114","author":"Naumann","year":"2009","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0b013e318234f927_bb0040","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ygyno.2005.11.013","article-title":"Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group study","volume":"100","author":"Walker","year":"2006","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0b013e318234f927_bb0045","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/jnci\/djg036","article-title":"A randomized clinical trial of cisplatin\/paclitaxel versus carboplatin\/paclitaxel as first-line treatment of ovarian cancer","volume":"95","author":"du Bois","year":"2003","journal-title":"J Natl Cancer Inst."},{"key":"10.1097\/IGC.0b013e318234f927_bb0050","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study","volume":"21","author":"Ozols","year":"2003","journal-title":"J Clin Oncol."},{"key":"10.1097\/IGC.0b013e318234f927_bb0055","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.1989.7.11.1748","article-title":"Carboplatin dosage: prospective evaluation of a simple formula based on renal function","volume":"7","author":"Calvert","year":"1989","journal-title":"J Clin Oncol."},{"key":"10.1097\/IGC.0b013e318234f927_bb0060","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockroft","year":"1976","journal-title":"Nephron."},{"key":"10.1097\/IGC.0b013e318234f927_bb0065","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0090-8258(03)00377-9","article-title":"First-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: results of long-term follow-up","volume":"90","author":"Fujiwara","year":"2003","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0b013e318234f927_bb0070","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1136\/ijgc-00009577-200505000-00003","article-title":"Preliminary toxicity analysis of intraperitoneal carboplatin in combination with intravenous paclitaxel chemotherapy for patients with carcinoma of the ovary, peritoneum, or fallopian tube","volume":"15","author":"Fujiwara","year":"2005","journal-title":"Int J Gynecol Cancer."},{"key":"10.1097\/IGC.0b013e318234f927_bb0075","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1111\/j.1525-1438.2008.01192.x","article-title":"Combination chemotherapy of intraperitoneal carboplatin and intravenous paclitaxel in suboptimally debulked epithelial ovarian cancer","volume":"18","author":"Nagao","year":"2008","journal-title":"Int J Gynecol Cancer."},{"key":"10.1097\/IGC.0b013e318234f927_bb0080","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1111\/IGC.0b013e3181a29dfe","article-title":"Phase II study of intraperitoneal carboplatin with intravenous paclitaxel in patients with suboptimal residual epithelial ovarian or primary peritoneal cancer: a Sankai Gynecologic Cancer Study Group Study","volume":"19","author":"Fujiwara","year":"2009","journal-title":"Int J Gynecol Cancer."},{"key":"10.1097\/IGC.0b013e318234f927_bb0085","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1200\/JCO.1992.10.9.1485","article-title":"Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study","volume":"10","author":"Markman","year":"1992","journal-title":"J Clin Oncol."},{"key":"10.1097\/IGC.0b013e318234f927_bb0090","first-page":"3380","article-title":"Direct diffusion of cis-diamminedichloroplatinum(II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy","volume":"49","author":"Los","year":"1989","journal-title":"Cancer Res."},{"key":"10.1097\/IGC.0b013e318234f927_bb0095","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.ygyno.2005.06.055","volume":"99","author":"Miyagi","year":"2005","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0b013e318234f927_bb0100","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"N Engl J Med."}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24089060?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24089060?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1097\/IGC.0b013e318234f927","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:06:33Z","timestamp":1753229193000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24089060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["S1048891X24089060"],"URL":"https:\/\/doi.org\/10.1097\/igc.0b013e318234f927","relation":{},"ISSN":["1048-891X"],"issn-type":[{"type":"print","value":"1048-891X"}],"subject":[],"published":{"date-parts":[[2012,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intravenous\/Intraperitoneal Paclitaxel and Intraperitoneal Carboplatin in Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Carcinoma","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1097\/IGC.0b013e318234f927","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright Copyright \u00a9 2012 by IGCS and ESGO.","name":"copyright","label":"Copyright"}]}}